Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma that is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; and INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company has a collaboration with the National Trauma Institute to supply Intercept plasma for use in the plasma resuscitation without lung injury (PROpOLIs) clinical study. Cerus Corporation was founded in 1991 and is headquartered in Concord, California.

Date	Fund	Action	%
2023/06/06	ARKG	Buy	0.0004
2023/06/05	ARKG	Buy	0.0131
2023/03/20	ARKK	Buy	0.0136
2023/03/20	ARKG	Buy	0.0092
2023/03/17	ARKK	Buy	0.0049
2023/03/17	ARKG	Buy	0.0021
2023/03/16	ARKK	Buy	0.0004
2023/03/16	ARKG	Buy	0.0004
2023/03/13	ARKK	Buy	0.0001
2023/03/13	ARKG	Buy	0.0001
2023/03/10	ARKK	Buy	0.0069
2023/03/10	ARKG	Buy	0.0073
2023/03/09	ARKK	Buy	0.0125
2023/03/09	ARKG	Buy	0.0126
2023/03/08	ARKK	Buy	0.0144
2023/03/08	ARKG	Buy	0.0157
2023/03/07	ARKK	Buy	0.0144
2023/03/07	ARKG	Buy	0.0148
2023/03/06	ARKK	Buy	0.0172
2023/03/06	ARKG	Buy	0.018
2023/03/03	ARKK	Buy	0.0022
2023/03/03	ARKG	Buy	0.0022
2023/03/02	ARKK	Buy	0.0046
2023/03/02	ARKG	Buy	0.0048
2023/03/01	ARKK	Buy	0.01
2023/03/01	ARKG	Buy	0.0091
2023/01/26	ARKG	Buy	0.0082
2023/01/25	ARKG	Buy	0.0119
2023/01/24	ARKG	Buy	0.0072
2023/01/23	ARKG	Buy	0.0356